云顶新耀：嘉善工厂成功放行EVM14首批临床样品

Core Insights - The company, CloudTop New Horizon, has successfully released the first batch of clinical samples for its universal tumor therapeutic vaccine EVM14 at its Jiaxing factory, which will support clinical trials in both the US and China [1] - The CEO emphasized that the release of EVM14 samples showcases the company's end-to-end capabilities in its self-developed mRNA technology platform, providing a solid foundation for the independent research and development of core pipelines [1] - EVM14 targets multiple tumor-associated antigens and is intended for the treatment of various squamous cell carcinomas, including non-small cell lung cancer and head and neck cancer [1] Company Developments - In addition to EVM14, the company is developing several other mRNA therapeutic drugs related to tumors and autoimmune diseases, including personalized tumor therapeutic vaccine EVM16 and self-generated CAR-T products [2] - The Jiaxing production base, covering an area of 85 acres with a building area of 58,000 square meters and an investment exceeding 900 million yuan, supports the localized research, production, and commercialization of these products [2] - The production facility has been operational since December 2022 and is equipped with advanced production facilities and a comprehensive quality assurance system [2]